Previous studies have revealed that inhibiting NLRP3 inflammasome activation in macrophages and thereby attenuating myocardial IL‐1β and IL‐18 levels effectively ameliorates myocardial ischemic injury and pressure overload‐induced heart failure and cardiac remodeling.11, 12, 13. This evidence concerns the gene NLRP3 and heart failure.